Earnings ·
Reports Q3 revenue of $32.9M, GAAP basic EPS loss of $(0.04), affirms full-year guidance
GYREGyre Therapeutics, Inc.
Gyre Therapeutics reported third-quarter 2026 revenues of $32.9 million, a 1% increase from the prior year period, driven by higher ETUARY sales volumes that offset lower Contiva and Etorel revenues following China's national centralized procurement program. The company posted a GAAP basic net loss per share of $(0.04) and affirmed its full-year 2026 revenue guidance of $100.5 million to $111.0 million. Cash and equivalents stood at $98.8 million as of September 30, 2026. The company is a U.S. biopharmaceutical firm with commercial operations in China focused on protein degrader therapeutics.